EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparative efficacy of upadacitinib and nemolizumab in combination with background topical therapy in adults and adolescents with moderate-to-severe atopic dermatitis: a placebo-anchored matching-adjusted indirect comparison

Jonathan Silverberg, Christopher Bunick, Raj Chovatiya, Nina Magnolo, Diego Ruiz Dasilva, Wan-Ju Lee, Chao Li, Siran Fang, Ayman Grada, Brian Calimlim, April Armstrong

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s848

DOI: 10.25251/1xyhek54 ↗
AbstractBibliografische Angaben

Abstract

Background: Upadacitinib (UPA), a Janus kinase 1 inhibitor, and nemolizumab (NEMO), an interleukin-31 receptor alpha antagonist, are both approved for the treatment of moderate-to-severe atopic dermatitis (AD). A placebo-anchored matching-adjusted indirect comparison (MAIC) comparde efficacy of UPA versus NEMO in adults and adolescents with moderate-to-severe AD. Methods: In the AD Up Ph3 trial , adults and adolescents with moderate-to-severe AD received UPA 15mg (UPA15), UPA 30mg (UPA30), or placebo in combination with topical corticosteroids (TCS) for 16-weeks (W). Aggregate-level patient data for NEMO were collected from ARCADIA 1& 2 Ph3 trials, in which AD patients received NEMO 30mg or placebo in combination with TCS for 16Ws. Selection criteria included Eczema Area and Severity Index (EASI) ≥ 16, Investigator Global Assessment (IGA) of moderate/severe, Worst Pruritus Numerical Rating Scale (WP-NRS) ≥ 4, and body surface area (BSA) ≥ 10%. Upadacitinib patients were weighted to match NEMO baseline characteristics. Outcome measures included the Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations1 for moderate treatment targets (≥ 75% improvement in EASI [EASI 75], WP-NRS improvement ≥ 4 [∆WP-NRS ≥ 4], EASI 75 + ∆WP-NRS ≥ 4) and optimal treatment targets (≥ 90% improvement in EASI [EASI 90], WP-NRS < 2). Response rates for UPA vs NEMO used placebo-adjusted rates, statistical comparisons based on the risk difference (RD). Results: UPA demonstrated statistically significant superiority over NEMO across all outcomes at Week (W) 16, with benefits emerging by W2. At W16, matching-adjusted response rates for UPA were numerically higher than those reported for NEMO for EASI 75 (NEMO: 42.9%; UPA15: 68.3% | UPA30: 79.2%), EASI 90 (25.6%; 48.4% | 67.6%), ∆WP-NRS ≥ 4 (41.9%; 54.2% | 62.4%), WP-NRS < 2 (29.6%; 40.1% | 50.8%), and EASI 75 + ∆WP-NRS ≥ 4 (23.4%; 45.5% | 57.8%). Placebo-adjusted response rates were higher for UPA15 and UPA30 versus NEMO for EASI 75 (UPA15: +40.8% | UPA30: +51.8% vs NEMO: +13.4%), EASI 90 (+35.7% | +54.9% vs +8.0%), ∆WP-NRS ≥ 4 (+40.4% | +48.6% vs +24.0%), WP-NRS < 2 (+31.4% | +42.2% vs +18.3%), and EASI 75 + ∆WP-NRS ≥ 4 (+36.2% | +48.5% vs +12.8%) (Figure); RDs were statistically significant (p < 0.001) for these comparisons. Statistically significant RDs favoring UPA were observed at W2 for ∆WP-NRS ≥ 4 (UPA15 vs NEMO: RD = 10.7% [95% CI: 2.9, 18.4]; UPA30 vs NEMO: RD = 20.1% [95% CI: 12.0, 28.1]) and WP-NRS < 2 (9.9% [3.7, 16.2]; 15.4% [8.9, 22.0]), and at W4 for EASI 75 (39.2% [30.4, 48.0]; 51.3% [42.9, 59.6]), EASI 90 (23.4% [16.3, 30.4]; 42.2% [34.6, 49.8]), and EASI 75 + ∆WP-NRS ≥ 4 (27.1% [19.3, 34.9]; 38.8% [30.8, 46.8]). Statistically significant differences for UPA15 and UPA30 versus NEMO were sustained through W16 for all outcomes assessed. Conclusions: Based on trials that included background topical therapy, adults and adolescents with moderate-to-severe AD achieved higher rates of moderate and optimal treatment targets with UPA15 and UPA30 compared with NEMO as early as W2 and through W16 in this placebo-anchored MAIC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →